Shasha Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shasha Zhao has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Chunji Gao
Chinese PLA General Hospital
1 shared publication - Daihong Liu
School of Medicine, Nankai University, Tianjin, China
1 shared publication - Dan-Dan Li
Department of Medical Ultrasound, Shanghai Tenth People's Hospital, Ultrasound Research and Education Institute, Tongji University School of Medicine, Shanghai, China
1 shared publication Huaping Wei
Department of Hematology Chinese People's Liberation Army (PLA) General Hospital Beijing China
1 shared publicationJialu Zhang
Beijing Children’s Hospital, Capital Medical University, Beijing, China
1 shared publicationJingyao Ma
Beijing Children’s Hospital, Capital Medical University, Beijing, China
1 shared publication
Latest Publications
- Open Access
- 1 January 2021
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Chronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes
The pathogenesis of chronic refractory immune thrombocytopenia (C/RITP) is mechanistically complex and considerably varies across patients. Few studies have focused on the genetic characteristics of C/RITP in children. The aim of this study was to analyze and summarize the clinical manifestations and genetic characteristics of C/RITP children with mutations in immune-related genes. In the study, 51 children with variants in immune-related genes (mutation group) and 103 children with no abnormal mutations (control group) were enrolled. Children in the mutation group showed severity of hemorrhage, a higher incidence of abnormal immunological indices, and an increased expression of SLE biomarkers. The number of peripheral T and B lymphocytes in the mutation group significantly increased. Nine patients (17.6%) had probable pathogenic variant genes associated with primary immunodeficiencies (TNFRSF13B, CARD11, CBL, and RAG2), and 42 patients (82.4%) had variants of uncertain significance in 23 genes. C/RITP patients with variants in immune-related genes had more severe bleeding, abnormal immunological indices, and an increased expression of SLE biomarker. Next-generation sequenciong (NGS) might be a useful way to differentiate those patients from C/RITP.
- 1 January 2021
- Published by SAGE Publications in Clinical and Applied Thrombosis/Hemostasis
- Vol. 27
Open AccessChronic Refractory Immune Thrombocytopenia Is Associated With Variants in Immune Genes
The pathogenesis of chronic refractory immune thrombocytopenia (C/RITP) is mechanistically complex and considerably varies across patients. Few studies have focused on the genetic characteristics of C/RITP in children. The aim of this study was to analyze and summarize the clinical manifestations and genetic characteristics of C/RITP children with mutations in immune-related genes. In the study, 51 children with variants in immune-related genes (mutation group) and 103 children with no abnormal mutations (control group) were enrolled. Children in the mutation group showed severity of hemorrhage, a higher incidence of abnormal immunological indices, and an increased expression of SLE biomarkers. The number of peripheral T and B lymphocytes in the mutation group significantly increased. Nine patients (17.6%) had probable pathogenic variant genes associated with primary immunodeficiencies (TNFRSF13B, CARD11, CBL, and RAG2), and 42 patients (82.4%) had variants of uncertain significance in 23 genes. C/RITP patients with variants in immune-related genes had more severe bleeding, abnormal immunological indices, and an increased expression of SLE biomarker. Next-generation sequenciong (NGS) might be a useful way to differentiate those patients from C/RITP.
- 9 April 2015
- Published by Wiley in Transfusion
- Vol. 55 (9) , 2134-2141
The efficacy and safety of sirolimus‐based graft‐versus‐host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta‐analysis of randomized controlled trials
BACKGROUND: The efficacy and safety of sirolimus (SIR)‐based graft‐versus‐host disease (GVHD) prophylaxis in patients who were subjected to allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain to be clarified; this meta‐analysis was conducted to evaluate these factors.STUDY DESIGN AND METHODS: Data from original research were obtained from PubMed, Embase, and Cochrane central register of controlled trials databases. Randomized controlled trials (RCTs) evaluating the efficacy of SIR‐based prophylaxis in allo‐HSCT were included. The risk ratio (RR), with a 95% confidence interval (CI), was used to pool data. The random effects model was used, irrespective of the presence or absence of heterogeneity.RESULTS: Five RCTs were included in the meta‐analysis. SIR was observed to significantly decrease the incidence of Grade II to IV acute GVHD (aGVHD; RR, 0.65; 95% CI, 0.47‐0.89). However, the incidence of Grade III to IV aGVHD and chronic GVHD was not decreased (RR, 0.91; 95% CI, 0.59‐1.40; RR, 1.04; 95% CI, 0.88‐1.23, respectively). An analysis of the toxic effects of SIR revealed that SIR effected a significant increase in the incidence of sinusoidal obstructive syndrome (RR, 2.24; 95% CI, 1.26‐4.01), while that of thrombotic microangiopathy was not significantly increased (RR, 2.48; 95% CI, 0.87‐7.06). Moreover, SIR did not improve event‐free survival and overall survival (RR, 0.97; 95% CI, 0.85‐1.10; and RR, 0.92; 95% CI, 0.82‐1.02, respectively).CONCLUSION: This meta‐analysis indicated that the SIR‐based regimen is an effective and safe alternative prophylaxis strategy for GVHD.
- 9 April 2015
- Published by Wiley in Transfusion
- Vol. 55 (9) , 2134-2141
The efficacy and safety of sirolimus‐based graft‐versus‐host disease prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation: a meta‐analysis of randomized controlled trials
BACKGROUND: The efficacy and safety of sirolimus (SIR)‐based graft‐versus‐host disease (GVHD) prophylaxis in patients who were subjected to allogeneic hematopoietic stem cell transplantation (allo‐HSCT) remain to be clarified; this meta‐analysis was conducted to evaluate these factors.STUDY DESIGN AND METHODS: Data from original research were obtained from PubMed, Embase, and Cochrane central register of controlled trials databases. Randomized controlled trials (RCTs) evaluating the efficacy of SIR‐based prophylaxis in allo‐HSCT were included. The risk ratio (RR), with a 95% confidence interval (CI), was used to pool data. The random effects model was used, irrespective of the presence or absence of heterogeneity.RESULTS: Five RCTs were included in the meta‐analysis. SIR was observed to significantly decrease the incidence of Grade II to IV acute GVHD (aGVHD; RR, 0.65; 95% CI, 0.47‐0.89). However, the incidence of Grade III to IV aGVHD and chronic GVHD was not decreased (RR, 0.91; 95% CI, 0.59‐1.40; RR, 1.04; 95% CI, 0.88‐1.23, respectively). An analysis of the toxic effects of SIR revealed that SIR effected a significant increase in the incidence of sinusoidal obstructive syndrome (RR, 2.24; 95% CI, 1.26‐4.01), while that of thrombotic microangiopathy was not significantly increased (RR, 2.48; 95% CI, 0.87‐7.06). Moreover, SIR did not improve event‐free survival and overall survival (RR, 0.97; 95% CI, 0.85‐1.10; and RR, 0.92; 95% CI, 0.82‐1.02, respectively).CONCLUSION: This meta‐analysis indicated that the SIR‐based regimen is an effective and safe alternative prophylaxis strategy for GVHD.